Search

Displaying results 4411 - 4420 of 5300 in total
  1. Drug

    GSK-923295

    go.drugbank.com/drugs/DB06097
    Investigational

    GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline … GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK.

  2. Drug

    Tozorakimab

    go.drugbank.com/drugs/DB16473
    Investigational

    Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. These trials include NCT03096795 (completed; h...

  3. Drug

    AGS-16C3F

    go.drugbank.com/drugs/DB17551
    Investigational

    AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate.

  4. Drug

    EGT-101

    go.drugbank.com/drugs/DB17645
    Experimental

    EGT-101 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the human sulfamidase (SGSH) transgene.

  5. Drug

    Oxomemazine

    go.drugbank.com/drugs/DB13820
    Investigational

    Oxomemazine is a phenothiazine derivative.

  6. Drug

    Sodium sulfide

    go.drugbank.com/drugs/DB11159
    Approved

    H2S is an endogenous gaseous transmitter that exhibits anti-inflammatory and antiapoptotic properties.

  7. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    [A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress.

  8. Drug

    Cefepime

    go.drugbank.com/drugs/DB01413
    ApprovedInvestigational

    [A249050] The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the

  9. Drug

    Temoporfin

    go.drugbank.com/drugs/DB11630
    Approved

    It was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan.

  10. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    Vanzacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) corrector. It is used alongside other CFTR correctors and CFTR potentiators to increase the quantity and function of CFTR at the cell surface in p...

    Synonyms: VX-121